There are calls for the Therapeutic Goods Administration (TGA) to greenlight a breakthrough medication with the potential to slow the progression of Alzheimer’s disease. The Federal Drug Administration (FDA) recently approved humanised monoclonal antibody Lecanemab for use in patients with the neurodegenerative disease, in the wake of promising clinical trial outcomes. The medication, marketed as…

Read More

Team VIVA! was dressed to impress at the annual PRIA Golden Target Awards (GTAs) held at the Sofitel Darling Harbour, Sydney, last night (Thursday, December 1, 2022).  A show-stopping 146 finalists representing 35 categories assembled for Australia’s longest-running, and most prestigious public relations and communications awards that both celebrate, and recognise, individuals, agencies and campaigns demonstrating strategic…

Read More

VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma,  and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel.   Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…

Read More

Concerningly, Australian GPs may be inadvertently placing themselves at increased risk of heart attack and stroke, according to new findings from the GP Health Initiative Report released this week, revealing one in seven (14%) GP respondents are not self-monitoring their blood pressure (BP) each year. According to the Servier-commissioned, quantitative, online survey conducted by Metis…

Read More

Yesterday, our team at VIVA! Communications had the privilege of partnering with Healthy Bones Australia to celebrate their 21 years of protecting Aussie bones. We coordinated a national news media announcement to mark this significant milestone, and announced the organisation’s new partnership with an Australian company to develop a breakthrough diagnostic fracture prediction tool. We…

Read More